NCT03246685 — Squamous Cell Carcinoma of the Head and Neck trial site landscape

Public-registry site landscape for NCT03246685, “Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD”, a Squamous Cell Carcinoma of the Head and Neck study sponsored by HiberCell, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT03246685 (registry record)
Study title	Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Official title	A Multicenter, Open-label, Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv Squamous Cell Carcinoma of H&N (SCCHN) Who Failed Pembro Monotherapy or Experiencing SD Following Completion of 4 to 8 Cycles of Pembro Monotherapy
Sponsor	HiberCell, Inc.
Condition(s)	Squamous Cell Carcinoma of the Head and Neck
Phase	PHASE2
Listed sites	1
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT03246685.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT03246685 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →